| Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos (t) ide therapy M Bazinet, V Pântea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Gastroenterology 158 (8), 2180-2194, 2020 | 201 | 2020 |
| Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in … M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Journal of Hepatology 66 (1), S256-S257, 2017 | 34 | 2017 |
| Analysis of HBsAg Immunocomplexes and cccDNA activity during and persisting after NAP‐based therapy M Bazinet, M Anderson, V Pântea, G Placinta, I Moscalu, V Cebotarescu, ... Hepatology Communications 5 (11), 1873-1887, 2021 | 13 | 2021 |
| Establishment of high rates of functional cure of HBeAg negative chronic HBV infection with REP 2139-Mg based combination therapy: ongoing follow-up results from the REP 401 study M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Age (average/median) 36, 36, 2019 | 13 | 2019 |
| Updated follow-up analysis in the REP 401 protocol: Treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and … A Vaillant, M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, ... Journal of Hepatology 68, S517, 2018 | 13 | 2018 |
| HBsAg isoform dynamics during NAP‐based therapy of HBeAg‐negative chronic HBV and HBV/HDV infection M Bazinet, M Anderson, V Pântea, G Placinta, I Moscalu, V Cebotarescu, ... Hepatology communications 6 (8), 1870-1880, 2022 | 12 | 2022 |
| Benefit of transaminase elevations in establishing functional cure of HBV infection during NAP‐based combination therapy M Bazinet, V Pântea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Journal of Viral Hepatitis 28 (5), 817-825, 2021 | 11 | 2021 |
| Preliminary safety and efficacy of REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated interferon alpha 2a in treatment naïve … M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Hepatology 64 (6), 1122A-1123A, 2016 | 9 | 2016 |
| Analysis of HBsAg levels, HBsAg isoforms, HBsAg immune complexes, HBV pregenomic RNA and HBcrAg dynamics during and after NAP-based combination therapy in the REP 301-LTF and … M Bazinet, M Anderson, V Pantea, G Placinta, I Moscalu, V Cebotarescu, ... Journal of Hepatology 73, S142, 2020 | 8 | 2020 |
| HBsAg, anti-HBs and ALT kinetic characterization during NAP-based combination therapy of HBeAg negative chronic hepatitis B infection L Hershkovich, L Shekhtman, M Bazinet, V Pantea, G Placinta, I Moscalu, ... JOURNAL OF HEPATOLOGY 75, S750-S751, 2021 | 5 | 2021 |
| Establishment of high rates of functional control and reversal of fibrosis following treatment of HBeAg negative chronic HBV infection with REP 2139-Mg/REP 2165-Mg, tenofovir … M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Hepatology 68, 234A-235A, 2018 | 5 | 2018 |
| Interim follow-up analysis in the REP 401 protocol: Functional control of HBeAg negative chronic HBV infection persists after withdrawal of combined therapy with REP 2139 or … M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Hepatology 66 (6), 1269A-1269A, 2017 | 5 | 2017 |
| Analysis of HbsAg isoforms during and after NAP-based combination therapy in the REP 301, REP 301-LTF and REP 401 studies M Bazinet, M Anderson, V Pântea, G Placinta, I Moscalu, V Cebotarescu, ... Hepatology 72, 500A-501A, 2020 | 1 | 2020 |
| Evaluation of the safety and tolerability of transaminase flares during antiviral therapy in patients with HBeAg negative chronic HBV infection or HBV/HDV co-infection M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Journal of Hepatology 70, E486-E486, 2019 | 1 | 2019 |
| Eficacitatea tratamentului cu preparate antivirale cu acţiune directă în hepatita virală C cronică I Russu, S Cojocaru, L Iarovoi, I Bîstrițchi, V Potîng-Rașcov, T Holban Culegere de articole știinţifice consacrată aniversării a 90-a de la …, 2017 | 1 | 2017 |
| Clinical and epidemiological features of acute hepatitis D viral in Republic of Moldova L Cojuhari, V Pântea, G Placintă, V Cebotarescu, L Iarovoi, O Mereuta, ... BMC Infectious Diseases 14 (Suppl 7), O12, 2014 | 1 | 2014 |
| Infecţia cu virusul gripal de tip nou A (H1N1) I Liviu, A Constantin, H Tiberiu, C Stela Analele Ştiinţifice ale USMF „N. Testemiţanu” 10 (3), 292-296, 2009 | 1 | 2009 |
| Noi tendințe de tratament în hepatita virală B+ D L Cojuhari, G Plăcintă, V Pântea, V Cebotarescu, L Iarovoi, A Vaillant, ... Sănătate Publică, Economie şi Management în Medicină 96 (3), 67-69, 2023 | | 2023 |
| Meningita criptococică la pacienții infectați cu HIV/SIDA L Iarovoi, A Nagîţ, N Minzatean, P Micșanschi, L Cojuhari, L Baba, ... Sănătate Publică, Economie şi Management în Medicină 96 (3), 70-73, 2023 | | 2023 |
| Eficacitatea tratamentului cu polimeri ai acizilor nucleici în hepatita virală b cronică aghbe negativă V Cebotarescu, G Plăcintă, V Pântea, L Cojuhari, L Iarovoi, V Smeşnoi, ... | | 2023 |
Lilia CojuhariAssociate professor, Nicolae Testemitanu State University of Medicine and PharmacyAdresă de e-mail confirmată pe usmf.md
